These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
555 related articles for article (PubMed ID: 33436624)
21. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19. Hashemian SM; Farhadi T; Velayati AA Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086 [TBL] [Abstract][Full Text] [Related]
22. Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex. Olotu FA; Omolabi KF; Soliman MES Cell Biochem Biophys; 2021 Jun; 79(2):175-187. PubMed ID: 33792836 [TBL] [Abstract][Full Text] [Related]
23. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Khan S; Attar F; Bloukh SH; Sharifi M; Nabi F; Bai Q; Khan RH; Falahati M Int J Biol Macromol; 2021 Jun; 181():605-611. PubMed ID: 33766591 [TBL] [Abstract][Full Text] [Related]
24. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. Gordon CJ; Lee HW; Tchesnokov EP; Perry JK; Feng JY; Bilello JP; Porter DP; Götte M J Biol Chem; 2022 Feb; 298(2):101529. PubMed ID: 34953856 [TBL] [Abstract][Full Text] [Related]
25. Mechanistic insight on the remdesivir binding to RNA-Dependent RNA polymerase (RdRp) of SARS-cov-2. Arba M; Wahyudi ST; Brunt DJ; Paradis N; Wu C Comput Biol Med; 2021 Feb; 129():104156. PubMed ID: 33260103 [TBL] [Abstract][Full Text] [Related]
26. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study. Wakchaure PD; Ghosh S; Ganguly B J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493 [TBL] [Abstract][Full Text] [Related]
27. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir. Tang W-F; Chang Y-H; Lin C-C; Jheng J-R; Hsieh C-F; Chin Y-F; Chang T-Y; Lee J-C; Liang P-H; Lin C-Y; Lin G-H; Cai J-Y; Chen Y-L; Chen Y-S; Tsai S-K; Liu P-C; Yang C-M; Shadbahr T; Tang J; Hsu Y-L; Huang C-H; Wang L-Y; Chen CC; Kau J-H; Hung Y-J; Lee H-Y; Wang W-C; Tsai H-P; Horng J-T Antimicrob Agents Chemother; 2024 Apr; 68(4):e0095623. PubMed ID: 38446062 [TBL] [Abstract][Full Text] [Related]
28. Structural Insights into Binding of Remdesivir Triphosphate within the Replication-Transcription Complex of SARS-CoV-2. Wang J; Shi Y; Reiss K; Maschietto F; Lolis E; Konigsberg WH; Lisi GP; Batista VS Biochemistry; 2022 Sep; 61(18):1966-1973. PubMed ID: 36044776 [TBL] [Abstract][Full Text] [Related]
29. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962 [TBL] [Abstract][Full Text] [Related]
30. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase. Wang Q; Wu J; Wang H; Gao Y; Liu Q; Mu A; Ji W; Yan L; Zhu Y; Zhu C; Fang X; Yang X; Huang Y; Gao H; Liu F; Ge J; Sun Q; Yang X; Xu W; Liu Z; Yang H; Lou Z; Jiang B; Guddat LW; Gong P; Rao Z Cell; 2020 Jul; 182(2):417-428.e13. PubMed ID: 32526208 [TBL] [Abstract][Full Text] [Related]
31. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307 [TBL] [Abstract][Full Text] [Related]
36. Mechanism of Inhibition of the Reproduction of SARS-CoV-2 and Wang J; Reiss K; Shi Y; Lolis E; Lisi GP; Batista VS Biochemistry; 2021 Jun; 60(24):1869-1875. PubMed ID: 34110129 [TBL] [Abstract][Full Text] [Related]
37. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases. Lo MK; Albariño CG; Perry JK; Chang S; Tchesnokov EP; Guerrero L; Chakrabarti A; Shrivastava-Ranjan P; Chatterjee P; McMullan LK; Martin R; Jordan R; Götte M; Montgomery JM; Nichol ST; Flint M; Porter D; Spiropoulou CF Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26946-26954. PubMed ID: 33028676 [TBL] [Abstract][Full Text] [Related]
38. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related]
39. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Martin R; Li J; Parvangada A; Perry J; Cihlar T; Mo H; Porter D; Svarovskaia E Antiviral Res; 2021 Apr; 188():105033. PubMed ID: 33549572 [TBL] [Abstract][Full Text] [Related]
40. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico. Elfiky AA; Azzam EB; Shafaa MW Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]